S&P 500   4,599.15 (+1.34%)
DOW   35,290.62 (+2.05%)
QQQ   386.20 (+0.80%)
AAPL   166.21 (+2.70%)
MSFT   324.12 (+0.34%)
FB   317.22 (+3.38%)
GOOGL   2,861.49 (+0.76%)
AMZN   3,459.50 (+2.06%)
TSLA   1,009.21 (-0.57%)
NVDA   295.77 (-3.64%)
BABA   122.08 (+9.04%)
NIO   32.22 (+0.22%)
CGC   10.16 (+1.70%)
AMD   137.75 (-4.35%)
GE   96.76 (+4.30%)
MU   82.68 (+1.30%)
T   23.45 (-0.04%)
F   19.36 (+1.15%)
DIS   150.54 (+2.95%)
PFE   52.17 (-3.87%)
AMC   29.15 (+0.48%)
ACB   5.96 (+2.41%)
BA   205.77 (+3.67%)
S&P 500   4,599.15 (+1.34%)
DOW   35,290.62 (+2.05%)
QQQ   386.20 (+0.80%)
AAPL   166.21 (+2.70%)
MSFT   324.12 (+0.34%)
FB   317.22 (+3.38%)
GOOGL   2,861.49 (+0.76%)
AMZN   3,459.50 (+2.06%)
TSLA   1,009.21 (-0.57%)
NVDA   295.77 (-3.64%)
BABA   122.08 (+9.04%)
NIO   32.22 (+0.22%)
CGC   10.16 (+1.70%)
AMD   137.75 (-4.35%)
GE   96.76 (+4.30%)
MU   82.68 (+1.30%)
T   23.45 (-0.04%)
F   19.36 (+1.15%)
DIS   150.54 (+2.95%)
PFE   52.17 (-3.87%)
AMC   29.15 (+0.48%)
ACB   5.96 (+2.41%)
BA   205.77 (+3.67%)
S&P 500   4,599.15 (+1.34%)
DOW   35,290.62 (+2.05%)
QQQ   386.20 (+0.80%)
AAPL   166.21 (+2.70%)
MSFT   324.12 (+0.34%)
FB   317.22 (+3.38%)
GOOGL   2,861.49 (+0.76%)
AMZN   3,459.50 (+2.06%)
TSLA   1,009.21 (-0.57%)
NVDA   295.77 (-3.64%)
BABA   122.08 (+9.04%)
NIO   32.22 (+0.22%)
CGC   10.16 (+1.70%)
AMD   137.75 (-4.35%)
GE   96.76 (+4.30%)
MU   82.68 (+1.30%)
T   23.45 (-0.04%)
F   19.36 (+1.15%)
DIS   150.54 (+2.95%)
PFE   52.17 (-3.87%)
AMC   29.15 (+0.48%)
ACB   5.96 (+2.41%)
BA   205.77 (+3.67%)
S&P 500   4,599.15 (+1.34%)
DOW   35,290.62 (+2.05%)
QQQ   386.20 (+0.80%)
AAPL   166.21 (+2.70%)
MSFT   324.12 (+0.34%)
FB   317.22 (+3.38%)
GOOGL   2,861.49 (+0.76%)
AMZN   3,459.50 (+2.06%)
TSLA   1,009.21 (-0.57%)
NVDA   295.77 (-3.64%)
BABA   122.08 (+9.04%)
NIO   32.22 (+0.22%)
CGC   10.16 (+1.70%)
AMD   137.75 (-4.35%)
GE   96.76 (+4.30%)
MU   82.68 (+1.30%)
T   23.45 (-0.04%)
F   19.36 (+1.15%)
DIS   150.54 (+2.95%)
PFE   52.17 (-3.87%)
AMC   29.15 (+0.48%)
ACB   5.96 (+2.41%)
BA   205.77 (+3.67%)
OTCMKTS:AGNPF

Algernon Pharmaceuticals Stock Forecast, Price & News

$3.18
-0.21 (-6.19%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.04
▼
$3.47
50-Day Range
$0.04
▼
$7.20
52-Week Range
$0.03
▼
$0.44
Volume
6,821 shs
Average Volume
492,228 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive AGNPF News and Ratings via Email

Sign-up to receive the latest news and ratings for Algernon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Algernon Pharmaceuticals logo

About Algernon Pharmaceuticals

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonÂ-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188 (N,N-Dimethyltryptamine), a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Headlines

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial
December 2, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals appoints former Medicure financial chief James Kinley as CFO
November 30, 2021 |  proactiveinvestors.com
Algernon Pharmaceuticals Announces New Chief Financial Officer
November 30, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest Up 1,175.0% in November
November 27, 2021 |  americanbankingnews.com
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
November 24, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Stock Set to Reverse Split on Wednesday, November 24th (OTCMKTS:AGNPF)
November 20, 2021 |  americanbankingnews.com
Algernon Pharmaceuticals Announces Share Consolidation
November 17, 2021 |  finance.yahoo.com
Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Expands By 200.0%
November 16, 2021 |  americanbankingnews.com
The Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest News
November 1, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
November 1, 2021 |  finance.yahoo.com
Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
October 26, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market
October 21, 2021 |  finance.yahoo.com
The Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News
October 15, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:AGNPF
Previous Symbol
CUSIP
N/A
CIK
1642178
Web
algernonpharmaceuticals.com
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Algernon Pharmaceuticals (OTCMKTS:AGNPF) Frequently Asked Questions

Are investors shorting Algernon Pharmaceuticals?

Algernon Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 15,300 shares, an increase of 1,175.0% from the October 31st total of 1,200 shares. Based on an average trading volume of 639,500 shares, the short-interest ratio is presently 0.0 days.
View Algernon Pharmaceuticals' Short Interest.

When did Algernon Pharmaceuticals' stock split? How did Algernon Pharmaceuticals' stock split work?

Algernon Pharmaceuticals's stock reverse split on the morning of Wednesday, November 24th 2021. The 1-100 reverse split was announced on Wednesday, November 24th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 24th 2021. An investor that had 100 shares of Algernon Pharmaceuticals stock prior to the reverse split would have 1 shares after the split.

Who are Algernon Pharmaceuticals' key executives?

Algernon Pharmaceuticals' management team includes the following people:
  • Mr. Christopher J. Moreau, CEO & Director (Age 55, Pay $212.8k)
  • Mr. Michael S. M. Sadhra CA, CPA, CFO & Director (Age 52, Pay $66.24k)
  • Dr. Christopher Bryan Ph.D., VP of Research & Operations
  • Dr. Ahmad Khalil, Chief Medical Officer

What is Algernon Pharmaceuticals' stock symbol?

Algernon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AGNPF."

How do I buy shares of Algernon Pharmaceuticals?

Shares of AGNPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Algernon Pharmaceuticals' stock price today?

One share of AGNPF stock can currently be purchased for approximately $3.18.

What is Algernon Pharmaceuticals' official website?

The official website for Algernon Pharmaceuticals is algernonpharmaceuticals.com.

Where are Algernon Pharmaceuticals' headquarters?

Algernon Pharmaceuticals is headquartered at 700 West Pender Street, Vancouver, BC V6C.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.